TMCnet News

Research and Markets: Hemophilia B Pipeline Review, H1 2015 - 17 Companies & 24 Drug Profiles
[July 09, 2015]

Research and Markets: Hemophilia B Pipeline Review, H1 2015 - 17 Companies & 24 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/9gjrnd/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-clas and best-in-class products.



Companies Involved in Therapeutics Development

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen, Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pharming Group N.V.
  • rEVO Biologics
  • Sangamo BioSciences, Inc.
  • Spark Therapeutics, Inc.
  • The International Biotechnology Center (IBC) Generium
  • uniQure N.V.

Drug Profiles


  • albutrepenonacog alfa
  • ALN-AT3
  • AMT (News - Alert)-060
  • AZ-10047130
  • BAX-335
  • BAY-1093884
  • CB-2679d
  • Cell Therapy for Hemophilia B
  • coagulation factor IX (recombinant)
  • coagulation factor VIIa (recombinant)
  • concizumab
  • CSL-689
  • DTX-101
  • Gene Therapy for Hemophilia B
  • Gene Therapy to Activate Factor IX for Hemophilia B
  • LR-769
  • MOD-5014
  • nonacog alfa biosimilar
  • nonacog beta pegol
  • PF-05280602
  • Recombinant Enzyme to Replace Factor IX for Hemophilia B
  • SHP-624
  • SPK-FIX
  • SVF-VIIa

For more information visit http://www.researchandmarkets.com/research/9gjrnd/hemophilia_b


[ Back To TMCnet.com's Homepage ]